MYB Antibody

說明書

中文名稱：

MYB兔多克隆抗體
貨號：

CSB-PA990239
規(guī)格：

￥1100
圖片：
Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela cells, Raji cells, Primary antibody: CSB-PA990239(MYB Antibody) at dilution 1/633, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

Uniprot No.：

P10242
基因名：

MYB
別名：

C myb antibody; c myb protein (140 AA) antibody; c-myb protein (140 AA) antibody; c-myb_CDS antibody; c-myb10A_CDS antibody; c-myb13A_CDS antibody; c-myb14A_CDS antibody; c-myb8B_CDS antibody; Cmyb antibody; efg antibody; Myb antibody; MYB proto-oncogene transcription factor antibody; MYB_HUMAN antibody; ONCOGENE AMV antibody; Oncogene MYB antibody; Proto oncogene c Myb antibody; Proto-oncogene c-Myb antibody; Transcriptional activator Myb antibody; v myb avian myeloblastosis viral oncogene homolog antibody; v-myb avian myeloblastosis viral oncogene homolog antibody
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse
免疫原：

Synthetic peptide of Human MYB
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,WB

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:1000-1:2000
WB	1:200-1:1000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'. Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells.
基因功能參考文獻(xiàn)：
1. found no significant differences in the genetic distribution and allelic frequency of MYB and SOX-6 gene polymorphisms PMID: 30200835
2. Salivary gland ACC cases expressing the MYB-NFIB chimeric gene showed significantly higher blood vessels density compared to non-expressing cases, and suggested that higher VEGF production capability in the former cases may be the cause. The findings also suggested that MYB-NFIB chimeric gene expression may be related to the onset age of ACC. PMID: 29243184
3. These results indicated that low expression of Mda-7/IL-24 along with high expression of C-myb are predictors for poor prognosis of Burkitt lymphoma patients; this outcome suggests that Mda-7/IL-24 and C-myb might be potential targets for clinical treatment of Burkitt lymphoma. PMID: 29415639
4. C-Myb expression in the laryngeal squamous cell carcinoma.YB-1 regulates miR-155 expression via c-Myb in the laryngeal squamous cell carcinoma. PMID: 29517281
5. Data indicate a pioneer factor model in which c-Myb binds to regions of closed chromatin and then recruits histone acetyltransferases. By binding to histones, c-Myb facilitates histone acetylation, acting as a cofactor for p300 at c-Myb binding sites. The resulting H3K27ac leads to chromatin opening and detachment of c-Myb from the acetylated chromatin. PMID: 29954426
6. Both cases harbored the MYB-NFIB gene fusion as demonstrated by FISH and RNA-sequencing PMID: 28210977
7. Expression of c-Myb, a regulatory factor of B lymphocytes, is increased in B lymphocytes of AIHA/Evans patients, while miR-150 expression is decreased. c-Myb was negatively correlated with miR-150. PMID: 29488168
8. genome-wide association analyses identified a new genome-wide significant locus on the HBS1L-MYB intergenic region for platelet-to-lymphocyte ratio PMID: 29066854
9. identified a high frequency of MYB rearrangements that promoted the MYB transcriptional activity in BPDCN. MYB split FISH analysis can constitute a valuable diagnostic tool for detecting MYB rearrangements PMID: 28344318
10. Studied association of BCL11A single nucleotide polymorphisms(snps) and HBS1L-MYB Intergenic snps with Hereditary Persistence of Fetal Hemoglobin (HPFH) in a cohort of sickle cell patients. PMID: 28332727
11. NFIB-associated gene rearrangement is a frequent genetic event in vulvar adenoid cystic carcinomas. Chromosome translocations involving NFIB but with an intact MYB indicate the presence of novel oncogenic mechanisms for the development of adenoid cystic carcinomas of the vulva. PMID: 27662035
12. Expression of the MYB-NFIB fusion oncogene in mammary tissue resulted in hyperplastic glands that developed into adenocarcinoma. PMID: 27213588
13. A trend toward superior PFS was noted with the MYB/NFIB rearrangement, although this was not statistically significant. NGS revealed three tumors with 4q12 amplification, producing increased copies of axitinib-targeted genes PDGFR/KDR/KIT. PMID: 27566443
14. Rearrangement of MYB did not affect OS. PMID: 28085142
15. Exosomes isolated from cultured AML or the plasma from mice bearing AML xenografts exhibited enrichment of miR-150 and miR-155. HSPCs cocultured with either of these exosomes exhibited impaired clonogenicity, through the miR-150- and miR-155-mediated suppression of the translation of transcripts encoding c-MYB PMID: 27601730
16. identification of SNPs within the IQCJ, NXPH1, PHF17 and MYB genes partly explaining the large interindividual variability observed in plasma triglyceride levels in response to an n-3 fatty acid supplementation PMID: 27160456
17. The data indicate that MAZ is essential to bypass MYB promoter repression by RB family members and to induce MYB expression. PMID: 28973440
18. deficiency alters the expression of a crucial subset of TAL1- and NOTCH1-regulated genes, including the MYB and MYC oncogenes, respectively. PMID: 28790107
19. A mutant of c-Myb, D152V, specifically affects c-Myb's ability to regulate genes involved in differentiation, causing failure in c-Myb's ability to block differentiation. PMID: 28472346
20. MYB acts on MAPK signaling by directly regulating transcription of the gene encoding the negative modulator SPRY2. PMID: 27748374
21. l genetic alterations were limited to two fusion genes, EWSR1-PATZ1 and SLMAP-NTRK2, both in gangliogliomas. Alterations in BRAF, FGFR1, or MYB account for most pathogenic alterations in low-grade neuroepithelial tumors PMID: 26810070
22. HBXIP up-regulates YAP expression via activating transcription factor c-Myb to facilitate the growth of hepatoma cells. PMID: 27765671
23. c-myb overexpression is associated with Breast Cancer Invasion and Metastasis. PMID: 27197202
24. This study assesses MYB, CD117 and SOX-10 expression in cutaneous adnexal tumors. PMID: 28098399
25. Molecular heterogeneity in the pathogenesis of sporadic and inherited cutaneous cylindromas, with convergence on MYB activation. PMID: 26969893
26. MYB as novel regulator of pancreatic tumor desmoplasia, which is suggestive of its diverse roles in Pancreatic Cancer pathobiology. PMID: 27246849
27. high-risk genotypes of six Hb F-associated SNPs, rs9376090, rs7776054, rs9399137, rs9389268, rs9402685 in the HBS1L-MYB intergenic region and rs189984760 in the BCL11A locus, showed association with high Hb F levels PMID: 28361591
28. A genome-wide association study (GWAS) identified loci associated with the plasma triglyceride (TG) response to omega-3 fatty acid (FA) supplementation in IQCJ, NXPH1, PHF17 and MYB. PMID: 28134766
29. The study shows that MYB gene breaks occur in 65% of ACC cases. MYB status very likely plays a role in the biological nature of ACC, leading to differences in survival. PMID: 27174194
30. The coexpression of GATA3 and MYB might be helpful in the distinction of primary cutaneous adnexal carcinoma versus metastatic breast, salivary gland, or urothelial carcinoma PMID: 28323779
31. hsamiR495 was downregulated in glioma tissues and cell lines, and acts as a tumor suppressor gene in glioma via the negative regulation of MYB. PMID: 27220777
32. Statistically significant negative association was found between the frequency of the c-Myb-positive tumor cells and the presence of distant metastases but not tumor differentiation, tumor stage, lymph node involvement, vascular invasion, tumor localization, age, and gender of the patients. No significant association between MYB mRNA and any clinicopathological characteristics was observed. PMID: 26873484
33. p38 and NOX1 are essential for the protective effect of c-Myb and that NOX1 acts upstream of p38 activation. PMID: 27107996
34. c-Myb is overexpressed in tracheobronchial and pulmonary adenoid cystic carcinomas. PMID: 27974718
35. The expression levels of two target genes, Myb and VEGFR2, were affected significantly by miR-16, while glucose administration inhibited miR-16 expression and enhanced tumor cell proliferation and migration. PMID: 26934556
36. All five successfully hybridized ACCs featured MYB rearrangement, whereas PLGAs did not show MYB rearrangement. Interestingly, one case of PLGA demonstrated a single intact copy of MYB in greater than 88% of the neoplastic cells. All ACCs exhibited consistent p63+/p40+ staining, whereas PLGAs demonstrated a p63+/p40- immunophenotype. PMID: 26711711
37. The MYB/MAF co-silencing constrained the skewing of erythroid versus megakaryocyte lineage commitment in MYB-silenced CD34+ cells, by restraining the expansion of megakaryocyte lineage while partially rescuing the impairment of erythropoiesis. PMID: 25857263
38. In summary, our results implicate that metastatic properties of some RMS subtypes might be linked to c-Myb function. PMID: 26462877
39. our study identifies super-enhancer translocations that drive MYB expression and provides insight into downstream MYB functions in alternate adenoid cystic carcinoma lineages. PMID: 26829750
40. MYB-QKI rearrangements promote tumorigenesis through three mechanisms: MYB activation by truncation, enhancer translocation driving aberrant MYB-QKI expression and hemizygous loss of the tumor suppressor QKI PMID: 26829751
41. PIAS1 enhances p300 recruitment to c-Myb-bound sites through interaction with both proteins. In addition, the E3 activity of PIAS1 enhances further its coactivation PMID: 27032383
42. MYB is aberrantly overexpressed in PC cells and acts as a key determinant of pancreatic tumour growth and metastasis PMID: 26657649
43. Our data suggest that c-Myb is a transcription factor with multifaceted target regulation depending on cell type. PMID: 26208222
44. Data show that Naphthol AS-E phosphate inhibits proto-oncogene protein Myb activity by disrupting its interaction with E1A binding protein p300. PMID: 25740244
45. In malignant spiradenocarcinoma, MYB expression was lost PMID: 25857824
46. Results indicate that cutaneous adenoid cystic carcinomas possess the same types of MYB alterations as ACCs of other anatomic sites. PMID: 26076064
47. miR-424 was involved in tumorigenesis of HCC at least in part by suppression of c-Myb. PMID: 24675898
48. results show that a p63(-) Myb(+) population of airway epithelial cells represents a distinct intermediate stage of differentiation PMID: 25103188
49. The study compares polymorphism at BCL11A to HBS1L-MYB loci and explains less of the variance in HbF in patients with sickle cell disease in Cameroon. PMID: 25488618
50. Authors observed that forced MYB-NFIB expression in human salivary gland cells alters cell morphology and cell adhesion in vitro and depletion of VCAN blocked tumor cell growth of a short-term ACC tumor culture. PMID: 25587024
顯示更多

收起更多
亞細(xì)胞定位：

Nucleus.
數(shù)據(jù)庫鏈接：

HGNC: 7545

OMIM: 189990

KEGG: hsa:4602

STRING: 9606.ENSP00000339992

UniGene: Hs.606320

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human